There is evidence from RCTs that rtCGM reduces HbA1c and increases TIR in people with type 2 diabetes treated with multiple daily injections [27] or basal insulin [9], and is more effective than SMBG in minimizing hypoglycemia for people using therapies at high hypoglycemic risk [28]. The gene discussed is INS; the disease is Hypoglycemia.